XC001 is designed to transiently grow new blood vessels to restore blood flow in the heart. It contains alternative splicing of the three isoforms of VEGF-A, which sets it apart from past attempts at ...

Final 12-month data from the EXACT trial demonstrates safety and efficacy results for a vascular endothelial growth factor ...

Compass gets US FDA fast track status for its bispecific DLL4/VEGF-A antibody, CTX-009 in combo with paclitaxel to treat biliary tract cancers: Boston Saturday, April 27, 2024, 12 ...

Medical College of Georgia scientists report that a gene previously implicated in the development of atherosclerotic lesions ...

Discover how Santen Pharmaceutical's monoclonal antibody targeting VEGF offers groundbreaking advancements in treating eye diseases and cancers.

Dear C.H.: Eylea is used to treat several cancers as well as the “wet” form of AMD. Eylea works by preventing the formation ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet ...

May 2, 2024 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $9.55 EPS, expectations were $10 ...

Back-of-the eye treatment company Opthea has taken this lore to heart, having rolled out three key opinion leaders – eye ...

Takeda (TAK) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of ...

Subscribe for FREE Anti-VEGF therapy, which blocks vascular endothelial growth factor and keeps excessive blood vessel growth ...